Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02266745 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

A Phase 2 study of Advanced Solid Tumors and Prostatic Neoplasms, sponsored by Promontory Therapeutics.

Active
Registry status
Phase 2
Development phase
109
Enrollment target
20
Study locations

NCT02266745 is a Phase 2 study of Advanced Solid Tumors and Prostatic Neoplasms that is active but no longer recruiting, run by Promontory Therapeutics. The registered enrollment target is 109 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02266745, a Phase 2 study of Advanced Solid Tumors and Prostatic Neoplasms, is active but no longer recruiting, sponsored by Promontory Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
109 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Injection and evaluate its safety and tolerability, and PK (pharmacokinetics). The Dose Escalation Phase is complete and no longer enrolling. The Dose Expansion Phase has two cohorts: one cohort for the study of PT-112 in patients with thymoma and thymic carcinoma (Cohort A), and one cohort for the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC) (Cohort D).

Conditions Studied

Advanced Solid Tumors Prostatic Neoplasms Neoplasms by Site Urogenital Neoplasms mCRPC Genital Neoplasms, Male Metastatic Castrate Resistant Prostate Cancer CRPC PT-112

Interventions

  • DRUG PT-112 Injection

Study Locations (20)

Other

  • Besançon - Besançon
  • Bordeaux - Bordeaux
  • Caen - Caen

Arizona

  • Arizona - Phoenix
  • Tucson - Tucson

Florida

  • Jacksonville - Jacksonville
  • Orlando - Orlando

Minnesota

  • Minneapolis - Minneapolis
  • Rochester - Rochester

New York

  • Brooklyn - Brooklyn
  • New York - New York

California

  • Duarte - Duarte

Colorado

  • Colorado - Aurora

Indiana

  • Indianapolis - Indianapolis

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2014-07
Est. Completion 2025-04-01
Phase Phase 2

Sponsor

Promontory Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02266745

The ClinicalTrials.gov registry entry for NCT02266745 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (45% lower). The listed sponsor is Promontory Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PT-112 Injection is the first listed.

NCT02266745 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT02266745 about?

NCT02266745 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts". This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose(s) (RP2D) of PT-112 Inject...

What is the current status of trial NCT02266745?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2014-07. Estimated completion is 2025-04-01.

What conditions does trial NCT02266745 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Prostatic Neoplasms, Neoplasms by Site, Urogenital Neoplasms, mCRPC.

What interventions are being tested in trial NCT02266745?

The interventions under investigation include: PT-112 Injection (DRUG).

Who is sponsoring clinical trial NCT02266745?

This trial is sponsored by Promontory Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02266745 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Prostatic Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.